alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 501–525 of 1,459 studies in Brain scans and imaging (page 21 of 59) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

What “Brain scans and imaging” covers

Brain scans and imaging — MRI, PET and other scans: what they show, how early, and how reliably.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurology 2005-03-01

The authors assessed whether measures of hippocampal water diffusivity at baseline can predict future progression to Alzheimer disease (AD) in amnestic mild cognitive impairment (aMCI). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Archives of neurology 2009-12-01

Clinical, cognitive, and CSF markers consistent with AD may precede detection of cerebral amyloid beta using amyloid imaging agents such as PiB that primarily label fibrillar amyloid beta plaques. 2 key findings →

Design: case report Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association between blood pressure, white matter lesions, and atrophy of the medial temporal lobe

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurology 2005-01-01

Blood pressure and indicators of small-vessel disease in the brain may be associated with atrophy of structures affected by Alzheimer pathology. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Magnetic resonance imaging of iron deposition in neurological disorders

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Topics in magnetic resonance imaging : TMRI 2006-02-01

Deposition of iron in the brain is proposed to play a role in the pathophysiology of the normal aging process and neurodegenerative diseases. 2 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2013-04-10

(18)F-AZD4694 showed reversible binding kinetics similar to (11)C-PiB, reaching an apparent steady state at 50 min after injection. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Increased cerebral metabolism after 1 year of deep brain stimulation in Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Archives of neurology 2012-09-01

Increased connectivity after 1 year of DBS is observed, which is in contrast to the decreased connectivity observed over the course of AD. 2 key findings →

Design: open-label trial Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Microstructural white matter changes in cognitively normal individuals at risk of amnestic MCI

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurology 2012-07-25

Microstructural white matter changes are present in cognitively normal individuals in the pre-aMCI stage, and may serve as a potential imaging marker of early AD-related brain changes. 1 key finding →

Participants: 193 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Effect of acupuncture in mild cognitive impairment and Alzheimer disease: a functional MRI study

✓ Peer-reviewed alzhub usefulness score 50 out of 100. PloS one 2012-08-20

We aim to clarify the mechanisms of acupuncture in treating mild cognitive impairment (MCI) and Alzheimer disease (AD) by using functional magnetic resonance imaging (fMRI). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Hippocampal and Amygdala Gray Matter Loss in Elderly Controls with Subtle Cognitive Decline

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Frontiers in aging neuroscience 2017-03-07

In contrast to the idea that hippocampal and amygdala volume loss occur in late phases of neurodegeneration, recent contributions point to the relevance of preexisting structural deficits that are associated with aging and are independent of amyloid deposition in preclinical Alzheimer disease cases. 5 key findings →

Participants: 455 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Heterogeneous histopathology of cortical microbleeds in cerebral amyloid angiopathy

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurology 2016-02-03

This study provides evidence for heterogeneous pathologic substrates and possibly different pathophysiologic mechanisms underlying MRI-observed cortical microbleeds in the context of advanced CAA and Alzheimer disease. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cross‐Sectional Comparison of Structural MRI Markers of Impairment in a Diverse Cohort of Older Adults

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Human Brain Mapping 2025-01-27

Higher BAG (pDeepBrainNet = 0.0002; pBrainAgeR = 0.00117) and lower hippocampal volume (p = 0.0015) and cortical thickness (p < 0.0001) were associated with worse clinical status (higher CDR). 2 key findings →

Participants: 2,870 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association of Superficial White Matter Microstructure With Cortical Pathology Deposition Across Early Stages of the AD Continuum

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurology 2025-06-19

Superficial white matter (SWM), containing short-range association connections beneath the cortex, has been affected in mild cognitive impairment and AD, with gaps in understanding the disease's early stages. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Diagnostic performance of MK and Flortaucipir tau PET for the biological staging of Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Alzheimer s & Dementia 2025-12-01

Clinical stages showed a progressively increased prevalence of Aβ-positivity and higher entorhinal tau PET pathology from cognitively normal (CN) to SOCD, MCI, and dementia in both tracers. 5 key findings →

Design: longitudinal study Participants: 446 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Artificial Intelligence–Powered Quantification of Flortaucipir PET for Detecting Tau Pathology

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Journal of Nuclear Medicine 2025-09-11

The AI-powered pipeline achieved robust performance with intraclass correlation coefficients exceeding 0.97 for regional uptake estimation compared with MR-based ground truth. 5 key findings →

Design: longitudinal study Participants: 666 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates.

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Journal of Neurology Neurosurgery & Psychiatry 1992-10-01

Magnetic resonance imaging (MRI) has shown a great reduction in medial temporal lobe and hippocampal volume of patients with Alzheimer's disease as compared to controls.

Full summary, score breakdown and related studies → Original source Free full text

Blood-brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Nature communications 2018-07-25

Magnetic resonance-guided focused ultrasound in combination with intravenously injected microbubbles has been shown to transiently open the blood-brain barrier, and reduce beta-amyloid and tau pathology in animal models of Alzheimer's disease. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 50 out of 100. International psychogeriatrics 2009-05-27

The participants comprising the AIBL cohort represent a group of highly motivated and well-characterized individuals who represent a unique resource for the study of AD. 1 key finding →

Participants: 1,000 Evidence: moderate

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed